Mologen AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.mologen.com
Clinical Trials
21
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Mologen AG
- Target Recruit Count
- 103
- Registration Number
- NCT02200081
- Locations
- 🇦🇹
Medizinische Universitaet Innsbruck, Innsbruck, Austria
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
🇩🇪Thoraxklinik Heidelberg gGmbH, Heidelberg, Baden Württemberg, Germany
Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: MGN1703 treatmentOther: Usual Maintenance
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Mologen AG
- Target Recruit Count
- 540
- Registration Number
- NCT02077868
- Locations
- 🇦🇹
Landesklinikum Krems, Krems, Austria
🇦🇹Kaiser-Franz-Josef-Spital, Vienna, Austria
🇦🇹Krankenhaus Hietzing, Vienna, Austria
A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703
- Conditions
- Healthy
- Interventions
- Drug: Placebo-MGNDrug: MGN-Placebo
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Mologen AG
- Target Recruit Count
- 14
- Registration Number
- NCT01982747
- Locations
- 🇺🇸
Spaulding Clinical, West Bend, Wisconsin, United States
A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)
- Conditions
- Stage IV Renal Cell Cancer
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Mologen AG
- Target Recruit Count
- 19
- Registration Number
- NCT01265368
- Locations
- 🇩🇪
Charité - Universtitäsmedizin Berlin, Klinik für Urologie, Berlin, Germany
🇩🇪Universitätsklinikum Bonn, Med. Klinik und Poliklinik, Hämatologie und Onkologie, Bonn, Germany
🇩🇪Medizinische Hochschule Hannover, Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation OE6860, Hannover, Germany
Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Mologen AG
- Target Recruit Count
- 59
- Registration Number
- NCT01208194
- Locations
- 🇦🇹
Klinik für Innere Medizin I, Abteilung für Klinische Onkologie, Medizinische Universität Wien, Wien, Austria
🇨🇿Oncology Clinic, Faculty Hospital Olomouc, Olomouc, Czech Republic
🇫🇷Service de Cancérologie Digestive, Institut de Cancérologie Gustave Roussy, Villejuif, France